Click any tag below to further narrow down your results
Links
AI has made generating hypotheses and running simulations cheap, but the actual experimental verification remains slow and expensive — a gap that will determine how much AI truly accelerates scientific discovery. The bottleneck isn't computing power; it's the physical work of building things, measuring them, and getting reproducible results.
- In formal math and software, verification is nearly free once problems are machine-checkable (Lean proofs, AlphaEvolve), so the limiting factor becomes compute. But most science requires physical experiments that can't be sped up by better algorithms.
- Amdahl's law shows the hard limit: if 80% of discovery time is lab work, infinitely fast hypothesis generation only delivers 1.25× speedup. Better models widen the verification gap rather than close it.
- Cheap compute creates "orphaned hypotheses" — promising candidates generated by grad students and small teams that go untested because experimental capacity is concentrated in a few rich institutions and countries. Accessible, affordable lab tools could democratize who can run the full loop of science.
- Surrogates like AlphaFold work only when built on high-quality experimental data and validated with real measurements. A country or company that scales compute without matching lab infrastructure and data capacity will have fast models that are confidently wrong.
@DAcemogluMIT on X
MIT economist Daron Acemoglu argues that promised AI drug discovery gains have so far been thin, and that the US could improve health far more cheaply by redirecting some AI spending toward public health. He points to the US life expectancy gap with peer countries, which mostly reflects preventable deaths rather than a lack of new treatments.
- A Hill and Stein paper finds no evidence yet that applied drug development is targeting proteins whose structures AlphaFold predicted.
- Daphne Koller notes AI work is concentrated on the last layer of drug development (new molecules for known modalities), not on understanding new disease mechanisms, where data is scarce.
- Americans live about five years less than citizens of Switzerland, Sweden, Japan, and similar countries, mostly from deaths before 70 due to chronic disease, overdoses, and other preventable causes.
@deedydas on X
At a San Francisco event, Demis Hassabis and Sebastian Mallaby covered AI's near-term risks, from OpenAI's finances to who controls powerful cyber tools. Hassabis also pitched Isomorphic Labs' drug discovery work and urged more careful, science-style decision-making on AI.
- Mallaby put the chance of OpenAI going bankrupt within 18 months at 50%.
- Hassabis said Isomorphic Labs needs six "AlphaFold" moments to shrink drug development from about 10 years to a few months.
- Mallaby argued it isn't tenable for a private company to decide who gets access to frontier cyber defense tools, since China could match them in 6 to 12 months.
- Hassabis rejected the 0% p(doom) view held by Marc Andreessen and Yann LeCun, calling it "crazy."